https://regulatorynews.com/lilly-foundayo-orforglipron-chmp-opinion Regulatory News en 2026-10-20T05:53:25-04:00 CHMP Recommends Lilly's Oral GLP-1 Foundayo https://regulatorynews.com/sequel-twiist-type2-diabetes-clearance Regulatory News en 2026-10-20T05:53:25-04:00 FDA Clears Twiist Pump for Type 2 Diabetes https://regulatorynews.com/ucb-zilbrysq-autoinjector-approval Regulatory News en 2026-10-20T05:53:25-04:00 FDA Approves Autoinjector for UCB's Zilbrysq https://regulatorynews.com/enspryng-satralizumab-thyroid-eye-disease-practice-impact Regulatory News en 2026-10-19T10:51:08-04:00 FDA Approves Enspryng, First At-Home Thyroid Eye Drug https://regulatorynews.com/microbiotica-mb310-series-c-financing Regulatory News en 2026-10-19T09:46:44-04:00 Microbiotica Raises £36M to Push MB310 to Phase 2 https://regulatorynews.com/fda-counterfeit-eye-drops-several-states Regulatory News en 2026-10-19T05:57:28-04:00 FDA Flags Counterfeit Eye Drops in Several States https://regulatorynews.com/fda-rare-disease-framework-initiative Regulatory News en 2026-10-19T05:57:28-04:00 FDA Launches Rare Disease Drug Review Framework https://regulatorynews.com/immunitybio-anktiva-papillary-nmibc-expansion Regulatory News en 2026-10-19T05:57:28-04:00 FDA Expands Anktiva to Papillary-Only Bladder Cancer